KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

West Pharmaceutical Services (WST) Debt to Equity (2016 - 2025)

West Pharmaceutical Services' Debt to Equity history spans 17 years, with the latest figure at $0.07 for Q3 2025.

  • For Q3 2025, Debt to Equity fell 9.77% year-over-year to $0.07; the TTM value through Sep 2025 reached $0.07, down 9.77%, while the annual FY2024 figure was $0.08, 198.91% up from the prior year.
  • Debt to Equity for Q3 2025 was $0.07 at West Pharmaceutical Services, down from $0.07 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.14 in Q1 2021 and bottomed at $0.03 in Q4 2023.
  • The 5-year median for Debt to Equity is $0.08 (2024), against an average of $0.08.
  • The largest annual shift saw Debt to Equity crashed 67.18% in 2023 before it soared 198.91% in 2024.
  • A 5-year view of Debt to Equity shows it stood at $0.11 in 2021, then dropped by 28.94% to $0.08 in 2022, then plummeted by 67.18% to $0.03 in 2023, then surged by 198.91% to $0.08 in 2024, then fell by 12.06% to $0.07 in 2025.
  • Per Business Quant, the three most recent readings for WST's Debt to Equity are $0.07 (Q3 2025), $0.07 (Q2 2025), and $0.08 (Q1 2025).